vTv Therapeutics Inc.
VTVT evidence brief
What we can confirm
- Market Cap:
- $126.4M
What it means
What to watch
Prepared research question
What matters most for VTVT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · VTVT
vTv Therapeutics Inc. is a late-stage biopharmaceutical company developing cadisegliatin, an oral investigational therapy for type 1 diabetes, with a pipeline that includes a Phase 2 trial in type 2 diabetes and an FDA Orphan Drug Designation for HPPD in sickle cell disease.
Key risk: No revenue, pre-commercial
Market Cap
$126.4M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 clinical trials for vTv Therapeutics Inc..
vTv Therapeutics Inc. is a late-stage biopharmaceutical company developing cadisegliatin, an oral investigational therapy for type 1 diabetes, with a pipeline that includes a Phase 2 trial in type 2 diabetes and an FDA Orphan Drug Designation for HPPD in sickle cell disease.
- Lead candidate cadisegliatin (TTP399) is a liver-selective glucokinase activator in Phase 3 for type 1 diabetes and has Breakthrough Therapy status [pipeline].
- Cash and equivalents were $86.6M as of 2026-06-30, with no revenue and a net loss of $13.1M [sec].
- A Phase 2 trial of cadisegliatin in type 2 diabetes (300 patients) was initiated in December 2025 with partner G42 Investments [sec_mda · as of 2026-05-13].
- FDA granted Orphan Drug Designation to HPPD for sickle cell disease in October 2026 [news · published 2026-10-07].
- The company expects to start registrational studies for cadisegliatin in type 1 diabetes in 2027 [sec_mda · as of 2026-05-13].
What works
- Cadisegliatin has received FDA Breakthrough Therapy designation, which may expedite development and review [pipeline].
- The company has a partnership with G42 Healthcare for development and commercialization in the Middle East, Africa, and Central Asia, providing a royalty stream [pipeline].
- Cash position of $86.6M as of 2026-06-30 provides a multi-year runway for ongoing clinical programs [sec].
What to weigh
- The company has no revenue from product sales and does not expect any until regulatory approval is obtained [sec_mda · as of 2026-08-06].
- Substantial additional funding will be needed to complete development and commercialization of its drug candidates [sec_mda · as of 2026-08-06].
- The successful development of clinical and preclinical candidates is highly uncertain, with no ability to reasonably estimate timing or costs [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
No revenue from product sales expected until regulatory approval
“We do not know when, or if, we will generate any revenue from drug product sales.”
SEC MD&A · August 6, 2026
Risks & what to watch (3)›
Key risks
- No revenue, pre-commercial — Company has no product revenue and expects none until regulatory approval, with expenses continuing to rise [sec_mda · as of 2026-08-06].
- Funding dependency — Substantial additional funding needed; capital availability depends on market price and trading volume of Class A common stock [sec_mda · as of 2026-08-06].
- Clinical trial uncertainty — Development timelines and costs are highly uncertain; cannot reasonably estimate when material net cash inflows may begin [sec_mda · as of 2026-08-06].
What to watch
- Initiation of screening for the Phase 2 T2D trial in the Middle East, expected in 2026 [sec_mda · as of 2026-05-13].
- Start of registrational studies for cadisegliatin in type 1 diabetes, expected in 2027 [sec_mda · as of 2026-05-13].
- Progress of partnering discussions for HPPD following Orphan Drug Designation [news · published 2026-10-07].
- Cash runway and any future financing activities as the company seeks additional funding [sec_mda · as of 2026-08-06].
Sources: News · Pipeline · SEC MD&A · Generated October 10, 2026 · How we verify sources →
Run vTv Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available vTv Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Short Interest
as of Apr 28, 2026- % of float
- 4.6%
- Days to cover
- 2.3
- Shares short
- 112,740
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
VTVT short interestGovernance
Frequently asked questions
What is the AI investment thesis for vTv Therapeutics Inc.?
vTv Therapeutics Inc. is a late-stage biopharmaceutical company developing cadisegliatin, an oral investigational therapy for type 1 diabetes, with a pipeline that includes a Phase 2 trial in type 2 diabetes and an FDA Orphan Drug Designation for HPPD in sickle cell disease.
Who is the CEO of vTv Therapeutics Inc.?
Mr. Paul J. Sekhri is the chief executive officer of vTv Therapeutics Inc. (VTVT).
Where is vTv Therapeutics Inc. headquartered?
vTv Therapeutics Inc. (VTVT) is headquartered in High Point, NC, United States.
What therapeutic areas does vTv Therapeutics Inc. focus on?
vTv Therapeutics Inc. develops therapies across Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.